Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714544 · ClinicalTrials.gov registry record · Phase 4
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Promius Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT01714544: Completed Phase 4 study of Psoriasis, sponsored by Promius Pharma.
NCT01714544 is a Phase 4 study of Psoriasis that has completed, run by Promius Pharma. The registered enrollment target is 60 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714544, a Phase 4 study of Psoriasis, has completed, sponsored by Promius Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
Primary Outcome
The proportion of subjects who demonstrate an IGA score of clear (0) or almost clear (1).
Conditions Studied
Interventions
- DRUG Cloderm Cream
Study Locations (5)
Texas
- DermResearch, Inc. - Austin
- Research Across America - Dallas
Ohio
- Radiant Research, Inc. - Cincinnati
Oregon
- Oregon Medical Research - Portland
Wisconsin
- Madison Skin and Research, Inc. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-10 |
| Phase | Phase 4 |
What the finished NCT01714544 record still lists
NCT01714544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Cloderm Cream is the first listed.
NCT01714544 lists 5 locations in 4 states (Texas, Ohio, Oregon).
Frequently Asked Questions
What is clinical trial NCT01714544 about?
NCT01714544 is a clinical study titled "Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis". The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
What is the current status of trial NCT01714544?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-10.
What conditions does trial NCT01714544 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01714544?
The interventions under investigation include: Cloderm Cream (DRUG).
Who is sponsoring clinical trial NCT01714544?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714544 being conducted?
This trial has 5 study locations across Ohio, Oregon, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01714544's enrollment target sits among peer trials
60 71st of 125 higher than 54 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia